Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 14 Researches
7.4
USERS' SCORE
Good
Based on 3 Reviews
8.4
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Milk Thistle Extract(Silybum marianum) (Fruit/Seed)(Standardized to 240 mg Silymarin Flavonoids - equivalent 80%)
300 mg
**
Dandelion Root (Taraxacum officinale)
100 mg
**
Artichoke (Cynara scolymus) (Leaf)
50 mg
**
Top Medical Research Studies
8
We investigated the potential of silibinin, a natural compound from milk thistle, in treating non-small cell lung cancer (NSCLC). Our study employed various assays to analyze how silibinin impacts cancer cell growth and migration.
We found that silibinin effectively inhibited the growth of NSCLC cells and suppressed important pathways linked to tumor progression. It worked by preventing tumor cells' ability to form new tumors and inhibited the expression of proteins associated with cancer growth.
Overall, silibinin shows promise as a candidate for both tumor immunotherapy and targeting cancer stem cells.
We found that silibinin effectively inhibited the growth of NSCLC cells and suppressed important pathways linked to tumor progression. It worked by preventing tumor cells' ability to form new tumors and inhibited the expression of proteins associated with cancer growth.
Overall, silibinin shows promise as a candidate for both tumor immunotherapy and targeting cancer stem cells.
Read More
8
Silymarin inhibits lung cancer mobility
We explored the effects of silymarin, a compound from the milk thistle plant, on the migration of non-small cell lung cancer (NSCLC) cells. In our study, we found that silymarin significantly inhibited cell movement in various NSCLC cell lines in a dose-dependent manner. This effect was linked to reductions in specific proteins that encourage cell movement, as well as an increase in tumor-suppressing microRNAs.
While promising, silymarin’s benefits in lung cancer treatment are still under investigation, and it may serve as a complementary treatment alongside conventional therapies.
While promising, silymarin’s benefits in lung cancer treatment are still under investigation, and it may serve as a complementary treatment alongside conventional therapies.
Read More
7
We explored the effects of silibinin, a compound derived from milk thistle, on the transcription factor ID3, which is known to promote cancer metastasis. Through various methods, including bioinformatics and lab assays, we assessed how silibinin could inhibit ID3 in non-small cell lung cancer (NSCLC) models.
Our findings suggest that while ID3 is difficult to target, silibinin shows promise as a potential treatment to reduce metastatic spread in lung cancer. This reveals an exciting avenue for further research into using silibinin as a therapeutic option.
Our findings suggest that while ID3 is difficult to target, silibinin shows promise as a potential treatment to reduce metastatic spread in lung cancer. This reveals an exciting avenue for further research into using silibinin as a therapeutic option.
Read More
Most Useful Reviews
9
Liver function improvement
1 people found this helpful
My sister is undergoing chemotherapy for lung cancer. Her liver enzyme levels increased after starting treatment, but after I suggested this product, her doctor prescribed it too. Now, her liver function is normal, and the chemotherapy is effective for her lung cancer.
Read More
7.5
Liver protection
2 people found this helpful
I have been taking milk thistle for a long time as I am a Hep B carrier. It has proven to protect the liver and reduce the risk of liver cancer. I highly recommend it.
Read More
7.5
Chemotherapy assistance
1 people found this helpful
I have colon cancer, and this product helps alleviate symptoms during chemotherapy.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 14 Researches
7.4
- All Researches
9
We screened 20 extracts from Middle Eastern plants to see how they affect lung cancer cells. Interestingly, 11 of these extracts showed promising results, demonstrating a strong cytotoxic effect. The most effective fractions showed their potential to induce cell death through apoptosis rather than necrosis.
While the results highlight the possible benefits of these plant extracts as supplementary options for lung cancer management, further investigation is needed to fully understand their impact and the safety for use in cancer treatment.
While the results highlight the possible benefits of these plant extracts as supplementary options for lung cancer management, further investigation is needed to fully understand their impact and the safety for use in cancer treatment.
Read More
8
We explored the effects of grape seed extract (GSE) and milk thistle extract (MTE) on lung cancer. Our study tested how these two extracts might work together to inhibit cancer cell growth in lab settings and in mice.
We found that when combined, GSE and MTE were effective in reducing tumor growth without causing toxicity. They helped raise levels of key tumor suppressors, which are important in fighting cancer.
Overall, this research encourages further investigation into using these natural extracts as potential treatments for lung cancer.
We found that when combined, GSE and MTE were effective in reducing tumor growth without causing toxicity. They helped raise levels of key tumor suppressors, which are important in fighting cancer.
Overall, this research encourages further investigation into using these natural extracts as potential treatments for lung cancer.
Read More
8
We investigated the potential of silibinin, a natural compound from milk thistle, in treating non-small cell lung cancer (NSCLC). Our study employed various assays to analyze how silibinin impacts cancer cell growth and migration.
We found that silibinin effectively inhibited the growth of NSCLC cells and suppressed important pathways linked to tumor progression. It worked by preventing tumor cells' ability to form new tumors and inhibited the expression of proteins associated with cancer growth.
Overall, silibinin shows promise as a candidate for both tumor immunotherapy and targeting cancer stem cells.
We found that silibinin effectively inhibited the growth of NSCLC cells and suppressed important pathways linked to tumor progression. It worked by preventing tumor cells' ability to form new tumors and inhibited the expression of proteins associated with cancer growth.
Overall, silibinin shows promise as a candidate for both tumor immunotherapy and targeting cancer stem cells.
Read More
8
Silymarin inhibits lung cancer mobility
We explored the effects of silymarin, a compound from the milk thistle plant, on the migration of non-small cell lung cancer (NSCLC) cells. In our study, we found that silymarin significantly inhibited cell movement in various NSCLC cell lines in a dose-dependent manner. This effect was linked to reductions in specific proteins that encourage cell movement, as well as an increase in tumor-suppressing microRNAs.
While promising, silymarin’s benefits in lung cancer treatment are still under investigation, and it may serve as a complementary treatment alongside conventional therapies.
While promising, silymarin’s benefits in lung cancer treatment are still under investigation, and it may serve as a complementary treatment alongside conventional therapies.
Read More
We examined how a special form of milk thistle called silibinin meglumine could impact non-small-cell lung carcinoma (NSCLC). In our study, this formulation reduced tumor sizes in mice just as effectively as a popular treatment called gefitinib.
What's fascinating is that silibinin meglumine not only controlled tumor growth but also helped prevent tumors from returning in cases resistant to gefitinib. Additionally, it showed potential in blocking a process called epithelial-to-mesenchymal transition, which often contributes to treatment resistance. This non-toxic option could pave the way for future clinical trials combining it with existing therapies for lung cancer.
What's fascinating is that silibinin meglumine not only controlled tumor growth but also helped prevent tumors from returning in cases resistant to gefitinib. Additionally, it showed potential in blocking a process called epithelial-to-mesenchymal transition, which often contributes to treatment resistance. This non-toxic option could pave the way for future clinical trials combining it with existing therapies for lung cancer.
Read More
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
9
Liver function improvement
1 people found this helpful
My sister is undergoing chemotherapy for lung cancer. Her liver enzyme levels increased after starting treatment, but after I suggested this product, her doctor prescribed it too. Now, her liver function is normal, and the chemotherapy is effective for her lung cancer.
Read More
7.5
Liver protection
2 people found this helpful
I have been taking milk thistle for a long time as I am a Hep B carrier. It has proven to protect the liver and reduce the risk of liver cancer. I highly recommend it.
Read More
7.5
Chemotherapy assistance
1 people found this helpful
I have colon cancer, and this product helps alleviate symptoms during chemotherapy.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Verdura S, Encinar JA, Gratchev A, Llop-Hernández À, López J, et al. Silibinin is a suppressor of the metastasis-promoting transcription factor ID3. Phytomedicine. 2024;128:155493. doi:10.1016/j.phymed.2024.155493
- Nazeam JA, El-Emam SZ. Middle Eastern Plants with Potent Cytotoxic Effect Against Lung Cancer Cells. J Med Food. 2024;27:198. doi:10.1089/jmf.2022.0098
- Mao JT, Xue B, Lu QY, Lundmark L, Burns W, et al. Combinations of grape seed procyanidin extract and milk thistle silymarin extract against lung cancer - The role of MiR-663a and FHIT. Life Sci. 2023;318:121492. doi:10.1016/j.lfs.2023.121492
- Rugamba A, Kang DY, Sp N, Jo ES, Lee JM, et al. Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells. Cells. 2021;10. doi:10.3390/cells10071632
- Verdura S, Cuyàs E, Ruiz-Torres V, Micol V, Joven J, et al. Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals (Basel). 2021;14. doi:10.3390/ph14060559
- Kaipa JM, Starkuviene V, Erfle H, Eils R, Gladilin E. Transcriptome profiling reveals Silibinin dose-dependent response network in non-small lung cancer cells. PeerJ. 2020;8:e10373. doi:10.7717/peerj.10373
- Singh T, Prasad R, Katiyar SK. Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression. Am J Cancer Res. 2016;6:1287.
- Son Y, Lee HJ, Rho JK, Chung SY, Lee CG, et al. The ameliorative effect of silibinin against radiation-induced lung injury: protection of normal tissue without decreasing therapeutic efficacy in lung cancer. BMC Pulm Med. 2015;15:68. doi:10.1186/s12890-015-0055-6
- Cufà S, Bonavia R, Vazquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, et al. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food Chem Toxicol. 2013;60:360. doi:10.1016/j.fct.2013.07.063
- Sadava D, Kane SE. Silibinin reverses drug resistance in human small-cell lung carcinoma cells. Cancer Lett. 2013;339:102. doi:10.1016/j.canlet.2013.07.017
- Li W, Mu D, Song L, Zhang J, Liang J, et al. Molecular mechanism of silymarin-induced apoptosis in a highly metastatic lung cancer cell line anip973. Cancer Biother Radiopharm. 2011;26:317. doi:10.1089/cbr.2010.0892
- Chen PN, Hsieh YS, Chiou HL, Chu SC. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact. 2005;156:141.
- Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, et al. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res. 2004;10:8641.
- Chu SC, Chiou HL, Chen PN, Yang SF, Hsieh YS. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog. 2004;40:143.
